title: Memantine in moderate-to-severe Alzheimer disease evidence and ethics based?
authors.forename: Marcel G
authors.initials: MG
authors.lastname: Rikkert
authors.forename: Wim J
authors.initials: WJ
authors.lastname: Dekkers
authors.forename: Philip
authors.initials: P
authors.lastname: Scheltens
authors.forename: Frans
authors.initials: F
authors.lastname: Verhey
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D023381:Endpoint Determination; D019317:Evidence-Based Medicine; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D006801:Humans; D018447:Medical Futility; D008559:Memantine / Q000627:therapeutic use*; D018579:Patient Selection; D012720:Severity of Illness Index
chemical_list: D018691:Excitatory Amino Acid Antagonists; D008559:Memantine